real peptides FAQ

Aliquot the solution into single-use volumes with 5–10% glycerol (v/v) or 5% trehalose (w/v) as a cryoprotectant, then freeze at −20°C or −80°C. Thaw one aliquot under refrigeration (not at room temperature) 12 hours before use. Each aliquot is used once and discarded. Never refrozen. This approach extends usable stability to 6–12 months at −20°C or up to 24 months at −80°C, but only if the freeze-thaw cycle is limited to once per aliquot. Alternatively, purchase smaller vial sizes matched to your experimental timeline. A 2 mg vial used within 14 days outperforms a 10 mg vial stored for 60 days.

Stop VIP immediately and return to the prerequisite step you skipped. Administering VIP while biotoxin levels remain elevated, MARCONS colonization persists, or MMP-9 stays above 332 ng/mL produces temporary symptom improvement followed by return to baseline within 2–4 weeks. This pattern—initial response followed by plateau or regression—indicates that ongoing inflammatory triggers overwhelm VIP's immunomodulatory capacity. The solution isn't higher VIP doses or more frequent administration; it's addressing the upstream pathology. Confirm through lab testing: C4a below 2,830 ng/mL, TGF-beta-1 under 2,380 pg/mL, negative MARCONS culture, and VCS scores normalized before restarting VIP therapy.

Discard it immediately and reconstitute a fresh peptide aliquot using a new bacteriostatic water vial. The 28-day USP standard exists because benzyl alcohol's bacteriostatic action degrades over time. After four weeks, bacterial inhibition drops below the threshold needed to prevent contamination from repeated needle punctures. Using expired bacteriostatic water introduces bacterial endotoxins into your peptide solution, which can produce inflammatory responses in test subjects that confound research outcomes. If you routinely have bacteriostatic water left over after 28 days, you're reconstituting too much peptide at once. Switch to smaller reconstitution volumes that align with your dosing schedule.

Discard the vial immediately and do not use it for any further reconstitutions. Visible particulates indicate either bacterial contamination, stopper coring, or protein aggregation from a previously reconstituted peptide. Bacteriostatic water should remain crystal clear throughout its 28-day use window. Cloudiness suggests the benzyl alcohol preservative has been overwhelmed by microbial growth, which occurs when contamination is introduced through improper needle handling or when the vial is used beyond the 28-day sterility window. Any peptides already reconstituted with that vial should be considered compromised and discarded as well.

Co-administer a DPP-IV inhibitor like sitagliptin or linagliptin. DPP-IV cleaves VIP at the N-terminus within minutes; inhibiting this enzyme extends the peptide's circulating half-life from 2–3 minutes to 8–12 minutes. Alternatively, switch to continuous subcutaneous infusion via osmotic minipump, which maintains stable plasma levels without requiring enzymatic protection. Many chronic autoimmune studies use 7-day or 14-day Alzet pumps loaded with VIP dissolved in sterile saline, delivering continuous low-dose infusion that sustains receptor activation far more effectively than multiple daily injections.

Discontinue enrollment and redesign endpoints around muscle quality rather than quantity. Muscle mass measured by DEXA or MRI doesn't distinguish between contractile myofibrils and non-functional sarcoplasmic hypertrophy. The type of growth that increases cross-sectional area without proportional force production. Earlier myostatin inhibitor trials fell into this trap. If Follistatin-344 clinical trials 2026 show lean mass gains but no improvement in NSAA score or six-minute walk distance, the FDA will not accept muscle mass as a surrogate endpoint. The corrective action: add dynamometry (direct strength measurement), muscle biopsy analysis for fiber type distribution and mitochondrial density, and contractile velocity testing. Functional hypertrophy requires concurrent resistance stimulus. Future trials may need to mandate physical therapy protocols alongside peptide administration.

Reassess reconstitution and storage protocol first. Temperature-induced degradation is the most common cause of non-response. Lyophilized follistatin-344 must be stored at −20°C before reconstitution; once mixed with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Any temperature excursion above 8°C during storage or transport denatures the glycoprotein structure irreversibly, rendering the peptide biologically inactive despite appearing visually unchanged. If storage protocol is confirmed intact, the second variable is dose adequacy: 100–200 mcg twice weekly may be subthreshold for certain models, particularly those with low baseline myostatin or high clearance rates. A 2019 study from the University of Texas found that dose-response curves for follistatin-344 showed steep increases in satellite cell activation between 200 mcg and 400 mcg per administration, then flattened above 500 mcg. Suggesting a therapeutic window exists and under-dosing produces partial activation that doesn't translate to hypertrophy.

Limit Epithalon cycles to 10–20 consecutive days followed by a 30–60 day washout period. Telomerase activation is tightly regulated in somatic cells for a reason. Continuous activation could theoretically bypass replicative senescence checkpoints that prevent uncontrolled cell division. While no evidence suggests Epithalon causes oncogenic transformation in normal cells, the precautionary principle recommends pulsed administration. NAD+ can be administered continuously or in cycles, but when you stack NAD+ Epithalon, the limiting factor is the Epithalon protocol. After 20 days, discontinue Epithalon and continue NAD+ alone if desired.

Discard the vial immediately—cloudiness indicates bacterial growth, oxidation, or peptide aggregation. NAD+ solutions should remain clear and colorless throughout the 28-day refrigerated storage window. Cloudiness suggests either contamination during reconstitution, repeated temperature excursions above 8°C, or use of non-bacteriostatic water. Do not inject cloudy peptide solutions; the risk of injection site reaction or systemic immune response outweighs any potential benefit from the degraded compound.

Account for the difference in selectivity and clearance kinetics when interpreting results. Myostatin-specific antibodies (like domagrozumab or landogrozumab) bind myostatin exclusively and have half-lives measured in days to weeks, requiring less frequent dosing but producing purely myostatin-mediated effects. Follistatin-344 has broader ligand binding (activin, GDF-11, BMP-7) and clears within hours, necessitating daily dosing but potentially producing additive hypertrophy through non-myostatin pathways. If your goal is isolating myostatin's role, the antibody is the cleaner reagent; if you're investigating maximal hypertrophic potential through multiple growth factor modulation, follistatin-344 is the appropriate choice.

No peer-reviewed evidence supports continuous Epithalon administration beyond 20 days per cycle. Published protocols by Khavinson used 10–20 day cycles specifically to avoid receptor desensitization or diminished telomerase response. Extending cycles to 30+ days may not increase benefit and could theoretically reduce the magnitude of effect observed in subsequent cycles. If longer intervention periods are desired, consider two 10-day cycles separated by a 4-week washout rather than a single extended cycle.

Contact the supplier immediately and request replacement. Do not use peptide that experienced temperature excursions during shipping. Real Peptides ships all SS-31 orders on dry ice with temperature data loggers that record the entire shipping environment; if our logger shows any period above 0°C, we automatically replace the shipment at no charge because we cannot guarantee peptide integrity. SS-31's Dmt residue oxidizes progressively at temperatures above 0°C, and that degradation is irreversible and invisible. Using compromised peptide wastes not just the peptide cost but the entire research protocol. Negative results from degraded SS-31 tell you nothing about the compound's actual efficacy.

Excessive cortisol suppression (below 20% of baseline) can impair immune function and metabolic regulation. Reduce the Selank dose by 30–40% while maintaining the Semax dose unchanged. The anxiolytic effect is dose-dependent but the cognitive synergy persists even at lower Selank concentrations. Monitor corticosterone levels in rodent models or salivary cortisol in primate studies to ensure the reduction stays within physiological range.

Discard the vial immediately. Cloudiness indicates protein aggregation or particulate contamination. Properly reconstituted peptides should produce clear, colorless solutions (some peptides like copper peptides may have slight blue or green tint due to metal complexation, but never cloudiness). Causes include: shaking the vial instead of swirling, injecting BAC water directly onto the peptide puck at high velocity, or temperature shock from using room-temperature BAC water on refrigerated peptide powder. Always bring both vials to room temperature before mixing.

SS-31 penetrates the blood-brain barrier and concentrates in neuronal mitochondria, making it particularly relevant for Alzheimer's, Parkinson's, and age-related cognitive decline models. Synaptic mitochondria in aged brains show pronounced cristae disruption and cardiolipin loss, correlating with impaired neurotransmitter release and dendritic spine retraction. Preclinical Alzheimer's models treated with SS-31 show reduced tau hyperphosphorylation and amyloid plaque formation alongside improved mitochondrial structure. Suggesting that energetic support may influence protein aggregation pathways. For laboratory protocols focused on neurodegeneration, SS-31 dosing typically ranges from 3–5 mg/kg subcutaneously in rodent models, with measurable effects on hippocampal ATP levels appearing within 2–4 weeks.

Use VPAC2-selective agonists like Ro 25-1553 or BAY 55-9837 instead of native VIP. These compounds demonstrate 100–300× selectivity for VPAC2 over VPAC1, allowing localized effects at the uterine or ovarian level while minimizing T-cell and macrophage modulation that occur through VPAC1 in lymphoid tissues. This approach is critical in reproductive immunology studies where the goal is maternal-fetal tolerance without broader immunosuppression that could increase infection risk.

Aliquot the reconstituted solution into single-use volumes and freeze at −20°C or −80°C. While refrigerated VIP degrades within 7–10 days, frozen aliquots maintain 85–95% bioactivity for 3–6 months when stored at −80°C without freeze-thaw cycles. The critical rule: never refreeze a thawed aliquot. Prepare enough single-use aliquots that each experimental day uses one freshly thawed vial. Thaw at 2–8°C (never at room temperature or in water bath), use within 4 hours, and discard any unused portion. Researchers using this aliquoting strategy report significantly better assay-to-assay consistency across multi-month studies compared to working from a single refrigerated stock that degrades progressively.

Cease further injections at the affected site immediately and document the reaction with photographs and clinical notes. Persistent induration lasting beyond 14 days may indicate a localized inflammatory response or, in rare cases, granuloma formation. Neither of which has been formally characterized in follistatin-344 literature but both of which are recognized complications of intramuscular peptide administration in general. Apply warm compresses to promote circulation and consider ultrasound evaluation if the induration does not resolve within four weeks. Do not re-inject the same anatomical location even after resolution; rotate injection sites across multiple muscle groups (deltoid, vastus lateralis, gluteus medius) to minimize cumulative local trauma. If systemic symptoms develop. Fever, malaise, or signs of infection. Obtain a complete blood count and inflammatory markers (CRP, ESR) to rule out abscess or cellulitis, and consult an infectious disease specialist if indicated.

Require updated tumor marker surveillance and cross-sectional imaging before clearance. Tumor dormancy is not the same as cure. Microscopic residual disease can persist asymptomatically for years, maintained in a quiescent state by immune surveillance and lack of angiogenic signals. VIP's VEGF-stimulating effects could theoretically reactivate dormant tumor cells by promoting neovascularization. For breast cancer survivors, obtain mammography and serum CA 15-3 or CA 27-29. For prostate cancer, check PSA and digital rectal exam. For colorectal cancer, colonoscopy and CEA. If all markers are undetectable and imaging shows no structural recurrence, the subject may be cleared for VIP research with informed consent documenting the theoretical proliferative risk. Exclude subjects with detectable tumor markers or imaging findings suggestive of recurrence.

Plateau at day 14 suggests receptor saturation or compensatory downregulation rather than protocol failure. Institute a 7-day washout period, then resume at 70% of the original dose. Many labs find lower maintenance doses sustain peak effects without triggering adaptation. Alternatively, shift from daily dosing to every-other-day administration while maintaining the same per-dose amount, which extends the duration of effect without increasing total peptide exposure.